Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells

被引:30
作者
Yamamoto, W
Verweij, J
de Bruijn, P
de Jonge, MJA
Takano, H
Nishiyama, M
Kurihara, M
Sparreboom, A
机构
[1] Daniel den Hoed Klin, Rotterdam Canc Inst, Dept Med Oncol, NL-3008 AE Rotterdam, Netherlands
[2] Univ Rotterdam Hosp, NL-3008 AE Rotterdam, Netherlands
[3] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Biochem & Biophys, Hiroshima 7348553, Japan
[4] Showa Univ, Toyosu Hosp, Dept Internal Med, Tokyo 1358557, Japan
关键词
Caco-2; cells; intestinal transport; irinotecan (CPT-11); metabolism;
D O I
10.1097/00001813-200106000-00003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Irinotecan (CPT-11) is a camptothecin analog with low (about 10-20%) and variable oral bioavailability in animal models. Here, Caco-2 cells were used to evaluate the transepithelial transport of CPT-11 and its metabolites. Caco-2 cells demonstrated significant expression of P-glycoprotein (P-gp), multidrug resistance-associated protein and canalicular multispecific organic anion transporter. Both the lactone and carboxylate forms of CPT-11 and SN-38 were actively transported across the cell monolayers, mainly by the epical-localized P-gp pump. Cellular permeability of CPT-11 at a concentration of 17 muM converted from active to passive-diffusional transport between the 2 and 6 h exposure time points. Antiproliferative effects of CPT-11 were related to permeability of the lactone form, whereas for SN-38 efficacy was dependent on lactone accumulation. Exposure of CPT-11 with cyclosporin A significantly enhanced its efficacy, whereas this was not observed with verapamil and R101933, In contrast, SN-38 efficacy decreased in the presence of P-gp inhibitors due to active transport toward the basolateral side, thereby reducing drug accumulation. Hence, multiple-active transport systems could be demonstrated to be responsible for not only accumulation profiles but also cytotoxic efficacy of CPT-11 and SN-38 in the intestinal Caco-2 cells. It is suggested that CPT-11 might act in a time-dependent manner and that SN-38-mediated cytotoxicity relates to (dose-dependent) lactone kinetics. The results detailed in this report could contribute toward the development of a clinically useful oral formulation of CPT-11 with improved absorption characteristics and suggest that cyclosporin A is a suitable agent for further research of this concept, [(C) 2001 Lippincott Williams & Wilkins.].
引用
收藏
页码:419 / 432
页数:14
相关论文
共 33 条
[1]  
AKIMOTO K, 1994, CHEM PHARM BULL, V42, P2135, DOI 10.1248/cpb.42.2135
[2]   Kinetics of lactone hydrolysis in antitumor drugs of camptothecin series as studied by fluorescence spectroscopy [J].
Chourpa, I ;
Millot, JM ;
Sockalingum, GD ;
Riou, JF ;
Manfait, M .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 1998, 1379 (03) :353-366
[3]  
Chu XY, 1999, J PHARMACOL EXP THER, V288, P735
[4]   Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus [J].
Ciotti, M ;
Basu, N ;
Brangi, M ;
Owens, IS .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 260 (01) :199-202
[5]   Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection [J].
deBruijn, P ;
Verweij, J ;
Loos, WJ ;
Nooter, K ;
Stoter, G ;
Sparreboom, A .
JOURNAL OF CHROMATOGRAPHY B, 1997, 698 (1-2) :277-285
[6]   Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors [J].
Drengler, RL ;
Kuhn, JG ;
Schaaf, LJ ;
Rodriguez, GI ;
Villalona-Calero, MA ;
Hammond, LA ;
Stephenson, JA ;
Hodges, S ;
Kraynak, MA ;
Staton, BA ;
Elfring, GL ;
Locker, PK ;
Miller, LL ;
Von Hoff, DD ;
Rothenberg, ML .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :685-696
[7]  
Gupta E, 1996, CANCER RES, V56, P1309
[8]  
GUPTA E, 1994, CANCER RES, V54, P3723
[9]   Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake [J].
Gutmann, H ;
Fricker, G ;
Török, M ;
Michael, S ;
Beglinger, C ;
Drewe, J .
PHARMACEUTICAL RESEARCH, 1999, 16 (03) :402-407
[10]  
Haaz MC, 1998, CANCER RES, V58, P468